Ribavirin ANDAs Still Waiting For FDA; Other Generic Issues Have Priority
FDA's final decision on the approvability of ANDAs for ribavirin is taking longer than expected while the agency resolves other complex generic drug issues
You may also be interested in...
The Healthcare Distribution Management Association has named Chief Operating Officer Nancy Hanagan to serve as interim CEO while the association searches for a successor to Ron Streck
The delay in approval for generic versions of Schering-Plough's Rebetol (ribavirin) illustrates one limitation of FDA's revised Waxman/Hatch regulations
A federal judge must determine whether CollaGenex' Periostat is properly classified as an "antibiotic" after preliminarily enjoining FDA from approving generic versions of doxycycline hyclate 20 mg